We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

The discovery, of course, goes beyond those taking GLP-1 medications. And while the BCL6 discovery came through a study on mice, researchers are confident it will translate to human physiology.

In order to connect human genetics with postulated biological pathways of GIP antagonism, Helicore has studied HCR-188 in combination with GLP-1 in preclinical models ... including in fat and in deep ...

DTC Telehealth Platforms - Arrangements involving telemedicine and direct-to-consumer (“DTC”) business services are expected to be a source ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

The main difference between collagen and whey protein is their amino acid profile and health benefits. Collagen's amino acids ...

The New Science of Ageing and the Quest for Immortality', he talked about ethics & realities of anti-ageing research and how to live a healthy, long life.

Consolidated gross profit margin was 3.11%, a decrease of 20 basis points driven by the continued increase in sales of low margin GLP-1 products combined ... driven by growth at our human health ...